Ciba Finds Biosignal Compounds "Exceptional" Against Microbes In Swiss Study
Main Category: Infectious Diseases / Bacteria / VirusesAlso Included In: Biology / Biochemistry
Article Date: 22 Nov 2007 - 2:00 PDT
| Patient / Public: | ![]() |
4 (2 votes) |
| Healthcare Prof: | ![]() |
3 (1 votes) |
Testing by Ciba Specialty Chemicals in its laboratory in Basel, Switzerland has shown that Biosignal's compounds have exceptional activity against micro-organisms.
The work has been conducted under the joint development agreement signed between Biosignal and Ciba in March 2006. Completion of these studies marks progression to the next phase of the collaboration and triggers a milestone and further work payments to Biosignal.
Two of Biosignal's lead compounds were formulated into PVC plastic and were able to completely inhibit growth on the material's surface. The results compare favourably with those achieved using existing products, many of which suffer flaws such as toxicity. This work confirms earlier strong in vitro activity and opens a range of product opportunities for Biosignal and Ciba.
"These are truly exceptional activity results and we are further developing the compounds under our joint agreement," said Ted Deisenroth, Technical Project Leader of the Bio-protection Group at Ciba Specialty Chemicals.
"Biosignal's industrial applications are accelerating on three fronts, consistent with the company's new focus. Oil & gas applications are rapidly progressing, major Japanese companies are adopting this technology as a product driver, and investing in Biosignal at the same time, and Ciba Specialty Chemicals is making excellent progress," said Peter Steinberg, CEO of Biosignal. "The industrial side of the business is building momentum."
Biosignal is currently discussing opportunities to fast track product development with Ciba. Biosignal will receive royalties on sales of Ciba products that include its compounds.
About Biosignal and the anti-biofilm technology
Biosignal's anti-biofilm technology is based on a discovery that the eastern Australian seaweed Delisea pulchra produces natural furanones that disable bacteria's ability to colonise. The fundamental problem with existing anti-bacterials, including antibiotics, is bacterial resistance. Bacteria rapidly produce resistant strains when faced with strong selective pressure by killing agents or growth-inhibitory agents. Furanones lull bacteria to inaction and appear to avoid the problem of bacterial resistance.
Biosignal produces synthetic compounds effective on inanimate surfaces such as pipes and membranes and animate surfaces such as lungs, skin and teeth. Biosignal's collaborations with US, European and Japanese companies are assessing new applications across a range of consumer and industrial products.
About Ciba Specialty Chemicals
Ciba Specialty Chemicals (SWX: CIBN, NYSE: CSB) is a leading global company dedicated to producing high-value effects for its customers' products. We strive to be the partner of choice for our customers, offering them innovative products and one-stop expert service. We create effects that improve the quality of life - adding performance, protection, colour and strength to textiles, plastics, paper, automobiles, buildings, home and personal care products and much more. Ciba Specialty Chemicals is active in more than 120 countries around the world and is committed to be a leader in its chosen markets. In 2005 the Company generated sales of CHF 7.4 billion and invested over CHF 300 million in R&D.
With the introduction of the SPAM Act aimed at reducing the number of unauthorised emails you receive, Monsoon Communications would like to send electronic communications to you only if you are interested in receiving them. If you would like to be removed from this mailing list please reply to this email with the word 'unsubscribe' in the subject field.
Ciba Specialty Chemicals
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/89621.php>
APA
http://www.medicalnewstoday.com/releases/89621.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




